anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Neuroinflammation is widely acknowledged as a characteristic feature of almost all neurological disorders and specifically in depression- and anxiety-like disorders. In recent years, there has been significant attention on natural compounds with potent anti-inflammatory effects due to their potential in mitigating neuroinflammation and neuroplasticity.
METHODS: In the present study, we aimed to evaluate the neuroprotective effects of oleacein (OC), a rare secoiridoid derivative found in extra virgin olive oil. Our goal was to explore the BDNF/TrkB neurotrophic activity of OC and subsequently assess its potential for modulating neuroinflammatory response using human neuroblastoma cells (SH-SY5Y cells) and an in vivo model of depression induced by lipopolysaccharide (LPS)-mediated inflammation.
RESULTS: In SH-SY5Y cells, OC exhibited a significant dose-dependent increase in BDNF expression. This enhancement was absent when cells were co-treated with inhibitors of BDNF's receptor TrkB, as well as downstream molecules PI3K and MEK. Whole-transcriptomics analysis revealed that OC upregulated cell cycle-related genes under normal conditions, while downregulating inflammation-associated genes in LPS-induced conditions. Furthermore, surface plasmon resonance (SPR) assays demonstrated that OC exhibited a stronger and more stable binding affinity to TrkB compared to the positive control, 7,8-dihydroxyflavone. Importantly, bioluminescence imaging revealed that a single oral dose of OC significantly increased BDNF expression in the brains of Bdnf-IRES-AkaLuc mice. Furthermore, oral administration of OC at a dosage of 10 mg/kg body weight for 10 days significantly reduced immobility time in the tail suspension test compared to the LPS-treated group. RT-qPCR analysis revealed that OC significantly decreased the expression of pro-inflammatory cytokines Tnfα, Il6, and Il1β, while simultaneously enhancing Bdnf expression, as well as both pro and mature BDNF protein levels in mice hippocampus. These changes were comparable to those induced by the positive control antidepressant drug fluoxetine. Additionally, microarray analysis of mouse brains confirmed that OC could counteract LPS-induced inflammatory biological events.
CONCLUSION: Altogether, our study represents the first report on the potential antineuroinflammatory and antidepressant properties of OC via modulation of BDNF/TrkB neurotrophic activity. This finding underscores the potential of OC as a natural therapeutic agent for depression- and anxiety-related disorders.
A decision support system is described that solves various technical problems associated with prior systems. The system may include a thin client application that downloads question sets from a server. The question sets may include a series of interlinked questions and answers as well as scores associated with the answers. Scores of selected answers may be tallied and a decision corresponding to the cumulative score of the selected answers may be provided to a user. As a result, the system may enable the ability to update (add, revise or delete) questions, answers and question lines without needing to recompile and redistribute the client application. In addition, the transmission of a complete question set reduces overall network traffic and technical problems arising from network disruptions among other technical benefits.
An injectable preparation comprising an antibody or antibody fragment, for use in a method of treating or reducing the risk of rheumatoid arthritis in a human. The antibody or fragment specifically binds an IL6R protein that comprises a mutation Asp358Ala or Val385Ile in SEQ ID NO. 78 and comprises a VH domain derived from the recombination of a human VH segment, a human D gene segment and a human JH segment. The human VH segment encodes a CDR1 comprising a Phe at position 4 shown in SEQ ID NO. 109. In this case, the human comprises a VH gene segment encoding a CDR1 comprising a Phe at position 4 shown in SEQ ID NO. 109, or the human expresses VH domains that comprise a CDR1 comprising a Phe at position 4 shown in SEQ ID No. 109. Alternatively, the human VH segment encodes a FW3 comprising a Thr at position 33 shown in SEQ ID NO. 111. In this alternative case, the human comprises a VH gene segment encoding a FW3 comprising a Thr at position 33 shown in SEQ ID NO. 111 or the human expresses VH domains that comprise a FW3 comprising a Thr at position 33 shown in SEQ ID No. 111. In both cases, the human comprises a nucleotide sequence encoding said IL6R protein comprising said Asp358Ala or Val385Ile in SEQ ID NO. 78.
A method is disclosed for using an artificial intelligence engine to onboard a user for an exercise plan. The method includes generating a machine learning model trained to receive as input onboarding data associated with a user and an onboarding protocol and, based on the onboarding data and the onboarding protocol, output an exercise plan. While a user performs an exercise using the exercise device, the method includes receiving the onboarding data associated with the user. The method includes determining, by the machine learning model using the onboarding data and the onboarding protocol, a fitness level of the user. The onboarding protocol includes exercises with tiered difficulty levels, the onboarding protocol increases a difficulty level for a subsequent exercise when an exercise is completed, and based on a completion state of a last exercise performed, the fitness level is determined. The method includes selecting a difficulty level for each exercise.
The invention is based on the construction of Tween80 biocompatible microemulsion, and the in vitro release and antioxidant performance of apigenin are researched. Tween80/IPM/PEG400/H is constructed by adopting pseudo-ternary phase diagram 2 O, and compartmentalized by conductivity, the microemulsion undergoes a structural transition from the bicontinuous phase (b.c.) to the O/W type. And then the O/W type microemulsion is selected as a carrier of the apigenin, and a saturated solubility experiment shows that the constructed microemulsion remarkably improves the solubility of the apigenin, and compared with the solubility in water, the microemulsion is used as the carrier to improve the solubility by 300 times. In vitro release experiments show that the microemulsion has a good slow release effect on the apigenin, and the release process of the apigenin in the microemulsion accords with first-order kinetics and is controlled by concentration diffusion. The medicine still has good antioxidant activity in microemulsion and has good ABTS resistance + Has better cleaning effect. The release rate, the accumulated release rate and the antioxidant activity of the apigenin in the microemulsion can be regulated and controlled by changing the mass ratio (S/O) of the surfactant to the oil, the water content and the like.
Very few youth with drug abuse or dependence in the United States receive treatment. This population of untreated youth represents a massive "treatment gap" in adolescent health care that renders impotent a potentially important avenue for preventing chronic drug abuse and related difficulties. The lack of motivation for treatment characterizing most adolescent drug abusers significantly decreases the likelihood these youth will enter treatment, barring mandates from the legal system or other social institutions. Efficacy studies have demonstrated that Community Reinforcement Training (CRT), an approach that involves teaching parents how to engage their youth into treatment, can work to recruit 60-80% of these treatment-elusive youth. CRT is traditionally provided in an individual therapy format to one or both parents. This study will improve upon our prior work by using a group format to provide a less costly procedure for engaging youth into treatment and to make it more portable to treatment agencies, schools, juvenile justice, and other community organizations seeking to offer support to parents or engage youth in treatment, thus significantly increasing the adoption and sustainability of the approach.

This study will examine the efficacy of the group format (G-CRT) for helping parents engage their unmotivated, resistant youth in treatment compared to the traditional individual format (I-CRT). Parents (n = 60) will be randomly assigned to G-CRT or to I-CRT. We will evaluate the differential efficacy of G-CRT, relative to I-CRT, on rates of adolescent engagement in treatment. We expect that G-CRT, compared to I-CRT, will also be associated with greater parent encouragement of adolescent sobriety, perceived social support, and family functioning. We also predict that changes on these process variables will predict increased success in engaging adolescents. We will also examine treatment outcomes for youth engaged in Cognitive Behavioral Therapy as a function of parental involvement in G-CRT or I-CRT. We predict enhanced support received by parents in G-CRT will result in greater reductions in drug use and lower levels of HIV-risk behaviors, outcomes hypothesized to be mediated by motivation to change and sessions attendance. Finally, we will conduct an informal cost-effectiveness analysis to derive preliminary estimates of the relative costs of each treatment modality per outcome unit and hypothesize that G-CRT will be more cost effective than I-CRT by virtue of having higher clinical effectiveness and lower costs. Successful outcomes here will provide the basis for a full clinical trial with larger samples.
A cross-sectional study design was used to describe the balance parameters and weight-bearing distributions on knee in different kneeling positions with different ankle conditions. The participants signed informed consent forms before the study was performed on a voluntary basis. Inclusion criteria were defined as being between 18-30 years old and not having knee pain with kneeling. Exclusion criteria were previous history of lower limb pain/pathology, trauma, and/or surgery, any neurological, rheumatological or oncological disorders that would affect balance, have performed high intensity physical activities last 72 hours before test day, and BMI \> 25. Balance parameters and weight distribution to each knee were evaluated three times at upright kneeling (UK) and full kneeling (FK) positions, in different ankle conditions (dorsiflexion and plantarflexion) with static balance device. Test-retest ICC values were calculated for all procedures.
Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
PURPOSE: A method for preparing essential oil of Abies holophylla MAX. leaves is provide to relieve skin pruritus and to promote skin metabolism. CONSTITUTION: A method for preparing essential oil of Abies holophylla MAX. leaves for relieving pruritus comprises: a step of washing and pulverizing Abies holophylla MAX. leaves; a step of mixing the pre-treated Abies holophylla MAX. with alcohol in a ratio of 1:1; a step of heating the Abies holophylla MAX. leaf solution at 90-110°C for 1-2 hours and collecting steam; and a step of cooling the steam at 0-20°C for 1-2 hours.
Abstract of the Disclosure This invention relates to compounds which have the following formula (I)   (I) wherein R, is a)  carboxy or b)  -COOR4, wherein R4 is C1-C12 alkyl or C3-C4 alkenyl; R2 is a') C1-C6 alkyl, which m?? be unsubstituted or substituted by C1-C2 alkoxy, or b')  C3-C4 alkenyl; R3 ?? C1-C4 alkyl, and the pharmaceuti-cally acceptable salts with bases.  It also relates to a process for the preparation of these compounds by the cyclization of a compound of formula (II)   (II) and where this step may be followed by the conversion of a compound of general formula (I) into a pharmaceutically acceptable salt or, the conversion of a salt into a free compound of formula I.  The compounds of this invention possess anti-allergic activity, which renders them useful in the prevention and treatment of bronchial asthma, allergic rhinitis, hay fever, urticaria and dermatosis.
Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
Provide a high protein food snack the first 2 weeks of each month for 6 months. Each participant will receive an 8 ounce food snack after dialysis for a total of 6 food snacks for each month.
MdDS is syndrome of oscillating vertigo following cessation of passive motion. The pathogenesis of this disorder is not well understood, but functional imaging studies suggest cortical connectivity dysfunction in feedback loops of the vestibulo-ocular system and visuo-spatial system. Patients go through multiple appointments and often specialist referrals before being diagnosed. After diagnosis, optimal management is difficult. Several treatment modalities, including medication, vestibular rehabilitation, and neuromodulation, have had variable success in management. We present the case of a young, female active duty Air Force Captain who developed symptoms while deployed. She underwent multiple treatments with variable success. Her clinical course highlights the difficulties for patients and providers posed by suspected MdDS.
Lung-resident macrophages, which include alveolar macrophages and interstitial macrophages (IMs), exhibit a high degree of diversity, generally attributed to different activation states, and often complicated by the influx of monocytes into the pool of tissue-resident macrophages. To gain a deeper insight into the functional diversity of IMs, here we perform comprehensive transcriptional profiling of resident IMs and reveal ten distinct chemokine-expressing IM subsets at steady state and during inflammation. Similar IM subsets that exhibited coordinated chemokine signatures and differentially expressed genes were observed across various tissues and species, indicating conserved specialized functional roles. Other macrophage types shared specific IM chemokine profiles, while also presenting their own unique chemokine signatures. Depletion of CD206hi IMs in Pf4creR26EYFP+DTR and Pf4creR26EYFPCx3cr1DTR mice led to diminished inflammatory cell recruitment, reduced tertiary lymphoid structure formation and fewer germinal center B cells in models of allergen- and infection-driven inflammation. These observations highlight the specialized roles of IMs, defined by their coordinated chemokine production, in regulating immune cell influx and organizing tertiary lymphoid tissue architecture.
Conventional Hemodialysis - 3 treatments per week for approximately 4 hours- will be performed in a dialysis clinic using any hemodialysis machine. Short Daily Hemodialysis - 5 or 6 treatments per week for approximately 2-4 hours per treatment- will be performed in the patient's home, using any hemodialysis machine. Partecipants randomized to SDHD will undergo an intensive home hemodialysis training program expected to take 2-6 weeks to complete. Qualified healthcare professionals will train each SDHD subject's partner to perform dialysis using any hemodialysis machine as chosen by clinicians. At baseline visit, before the first study treatment in either the SDHD or CHD arm, the following data will be collected: demographic information, ESRD history, EuroQol EQ-5D-5L questionnaire, vital sign, blood laboratory test results, KT/V parameters, 24 hour timed urine collection test results, comorbid conditions, vascular access type, current medications. After hemodialysis start, patients will be followed up to 12 months with data collection at 1,3,6 and 12 months. At each visit, the following data will be collected: EuroQol EQ-5D-5L questionnaire, vital sign, blood laboratory test results, KT/V parameters, 24 hour timed urine collection test results, adverse events, vascular access type, current medications. During this study, the following parameters will be strictly monitored: treatment costs, medications, number of hospitalization admissions, number of days in hospital and reasons for hospitalizations, additional costs informations.

Home hemodialysis could be an integrated therapeutic option favoring the de-hospitalization of patients requiring hemodialysis. Aim of this study is to offer the patient a better quality of life, to create the conditions for an improvement in blood pressure, phosphate control, of cardiovascular morbidity and mortality, and to reduce costs for the National Health Service.
NEW MATERIAL:The compound of formula I [R is H or lower alkyl; A is group of formula II (R<1> is H or lower alkyl) or -CO-]. EXAMPLE:2-Amino-7-( 1-hydroxy-1-methyl )-ethyl-5-oxo-5H-[ 1 ]benzopyrano[ 2,3-b]pyridine-3-carboxylic acid. USE:Anti-allergic agent. Useful as a preventive and remedy for allergic diseases such as allergic asthma, allergic dermatitis, hay fever, etc. PREPARATION:The compound of formula I can be prepared by hydrolyzing the compound of formula II (R<2> is lower alkyl). The alkali metal salt and organic amine salt of the compound of formula I have high solubility in water, and the solution has high stability. Accordingly the compound is convenient to be prepared in the form of drug such as injection, solution, etc.
In 2011 a Maternity Services Development Programme (MSDP) was implemented in one South of England city. The programme aimed to promote effective collaborative working between maternity services (midwives) and other service providers (health visitors, social workers, Children Centre staff, specialist and volunteer services) to improve outcomes for service users (women and families). The MSDP utilised local Children's Centres, which provide community focused family support, to co-locate maternity services and other service providers. The rationale to improve collaborative working is supported by evidence suggesting poor collaborative working contributes to poorer outcomes (Laming Report 2003; Marmot Review 2010). Therefore programmes such as the MSDP could potentially improve short and long-term outcomes for those accessing maternity services.

The proposed research uses a case study approach to collect and analyse predominantly qualitative data, and some quantitative data. This method will allow for analysis of the MSDP and understanding of its influence on maternity services and collaboration, and will aim to illuminate perceived strengths and challenges of the MSDP evident to services providers. Data will be collected using observation episodes (e.g. participant meetings) to observe collaboration, and interviews to explore experiences. Additionally documents will be analysed to observe documented evidence of collaborative practice. Pre-existing statistical data will also be used to highlight changes in indicators of service user well-being since the implementation of the MSDP.

The research will recruit a cross-section of service providers (no service users) that work in or with maternity services from four of the nine city Children Centres. Invitation letters will be circulated to potential participants through participating Children Centre management, where they will be invited to participate in the observation and interview data collection activities. They will then be able to select the extent of their participation.
Inclusion criteria will be health participants with age between 18 to 45 years. Exclusion criteria were a BMI higher than 31 kg/m2, hypocapnia, any musculoskeletal condition in lumbopelvic region, skin and lower limb pathology (i.e., fracture, surgery).

Initially, baseline measurements will make following Whittaker et al. guidelines to measure thickness of the abdominal wall muscles (external oblique, EO; internal oblique, IO; transversus abdominis, TrA and rectus anterior, RA). All evaluations will be carry out by a single operator (B.M.P), who was a specialized physical therapist with 3 years of USI experience. A diagnostic ultrasound tool (Toshiba Aplio 500 Platinum, Toshiba American Medical Systems; CA, USA) with a 7 to 14-MHz-range linear transducer (18L7 PLT-1204BT type; 40-mm footprint) will be used for B mode ultrasound imaging. Ultrasound images of the EO, IO and TrAb muscles will be taken with the patients in supine position, with a cross reference point placed between the iliac crest and the inferior border of subcostal line, and the midaxilary line on the right side ; RA muscle was aligned with the umbilicus; and interrecti distance (IRD) will be measured just under the umbilicus. The measure for the thickness during the rest condition will be perform by the mean of 3 repeated values for each measure at the end of expiration, maintaining the transducer at the same point. Muscle thickness will be considered as the distance between the inside caliper lines of each muscle border. IRD will be described as the distance between the inside caliper lines of each RA muscles.

Once baseline measurements will be taken, the same measurements will make while the patients perform the exercise. This exercise specifically targets the abdominal wall muscles (EO, IO, TrA and RA). At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal draw in maneuver (ADIM) was developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject will be practiced the ADIM three times with an ultrasound image feedback.
BACKGROUND: Extra-fine particle inhaled corticosteroids (ICS) improve peripheral airway distribution, but their effect on risk of exacerbations and all-cause mortality in patients with chronic obstructive pulmonary disease (COPD) is unclear.
METHODS: This observational cohort study compares patients with COPD who received extra-fine particle ICS to those who received standard particle size ICS from 2010 to 2017 while followed in outpatient clinics. The primary outcome was the time to a COPD exacerbation that required hospitalization, with all-cause mortality as a secondary outcome. Data were analyzed using an adjusted Cox proportional hazards model and a competing risk analysis. Two predefined subgroup analyses of patients treated with pressurised metered dose inhalers (pMDIs) and patients with a previous exacerbation history, was carried out. Lastly, we created a propensity score matched cohort as a sensitivity analysis.
RESULTS: Of the 40,489 patients included, 38,802 (95.8%) received stand particle size ICS and 1,687 (4.2%) received extra-fine particle ICS. In total 7,058 were hospitalized with a COPD exacerbation, and 4,346 died. No significant protective effect of extra-fine particle ICS against hospitalization due to COPD exacerbations (HR 0.93, 95% CI 0.82-1.05, p=0.23) or all-cause mortality (HR 1.00, 95% CI 0.85-1.17, p=0.99) was found when compared to standard particle size ICS. However, in the subgroup analysis of patients treated with pMDIs, extra-fine particle ICS was associated with reduction in risk of exacerbations (HR 0.72, 95% CI 0.63-0.82, p<0.001) and all-cause mortality (HR 0.72, 95% CI 0.61-0.86, p<0.001).
CONCLUSION: The administration of extra-fine particle ICS was not associated with reduced risk of exacerbations or all-cause mortality in our primary analysis. A subgroup consisting of patients treated with pMDIs suggested potential protective benefits.
Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.